Should the Lambda (λ) Remain Silent? Hossein Haji Ali AfzaliJonathan KarnonMark Sculpher Commentary 10 December 2015 Pages: 323 - 329
Richard Edlin, Christopher McCabe, Claire Hulme, Peter Hall, Judy Wright: Cost Effectiveness Modelling for Health Technology Assessment: A Practical Course Doug Coyle Book Review 28 January 2016 Pages: 331 - 332
Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility Alexander ThompsonBruce GuthrieKatherine Payne Current Opinion 08 December 2015 Pages: 333 - 336
The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence Joanne O’ConnorStephen RiceNerys Woolacott Review Article 27 January 2016 Pages: 337 - 348
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users P. VemerI. Corro RamosT. L. Feenstra Original Research Article Open access 11 December 2015 Pages: 349 - 361
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France Sylvain DruaisAgathe DoutriauxPascal Guillon Original Research Article Open access 16 February 2016 Pages: 363 - 391
What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study Anthony HarrisJing Jing LiKaren Yong Original Research Article 26 November 2015 Pages: 393 - 402
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa Ilanca FraserJohanita BurgerTienie Stander Original Research Article 14 December 2015 Pages: 403 - 417
Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review” Angelo Claudio PalozzoAndrea Messori Letter to the Editor 29 February 2016 Pages: 419 - 420
Authors’ Reply to Palozzo and Messori: ‘‘Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review’’ Bonny ParkinsonAdam G. Elshaug Letter to the Editor 29 February 2016 Pages: 421 - 422